Acura Pharma (ACUR) Misses Q1 EPS by 2c

Acura Pharma (NASDAQ: ACUR) reported Q1 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26).

As of April 30, 2016, our cash, cash equivalents and marketable securities less our compensating balance requirement of $2.5 million was $7.7 million, and we had $7.4 million in term debt financing.

For earnings history and earnings-related data on Acura Pharma (ACUR) click here.

You May Also Be Interested In

• VNET Group (VNET) Misses Q2 EPS by 164c
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance